Sanofi Australia

In 2013, 2012, 2011 and 2010 the Therapeutic Goods Administration's Complaints Resolution Panel upheld complaints about six ads by this company on the grounds that they breached advertising codes. The Panel requested this company withdraw the ads and not to use representations in the ads again.
Source: TGA Complaints Register (2013)

According to the democracyforsale.net website, this company donated $475,870 to Australia's major political parties between 2012 and 2018, as disclosed to the Australian Electoral Commision (AEC).
Source: Democracy For Sale (2018)

Australian Packaging Covenant Organisation (APCO) is a not-for-profit organisation leading the development of a circular economy for packaging in Australia. Each year, APCO Members are required to submit an APCO Annual Report and Action Plan, which includes an overall performance level from 1 (Getting Started) to 5 (Beyond Best Practice). This company received a packaging performance level of 2 (Good Progress) in its 2022 APCO Annual Report.
Source: APCO (2022)

This company is listed by the Workplace Gender Equality Agency (WGEA) as a Employer of Choice for Gender Equality citation holder. The citation is designed to encourage, recognise and promote active commitment to achieving gender equality in Australian workplaces.
Source: WGEA (2022)

This company has a number of social responsibility claims on its website.
Source: company website (2014)

Changing Markets' 2016 report, 'Superbugs in the Supply Chain' investigates how pollution from antibiotics factories in India and China is fuelling the global rise of drug-resistant infections. "Sanofi has links to dirty production via its Czech subsidiary Zentiva, which sources the antibiotic Ciprofloxacin from Neuland Pharmaceuticals - an Indian pharma company that has been implicated in unlawful manufacturing discharges."
Source: Changing Markets (2016)

In June 2015, Sanofi's Indian subsidiary was fined US$9.4m by the Indian Competition Commission for colluding and forming a cartel (with GlaxoSmithKline) in their bidding practices to get government contracts for the supply of a meningitis vaccine. The vaccine was for use among 200,000 pilgrims visiting Mecca.
Source: Fierce Pharma (2015)

The Court of Appeals of Paris upheld a 40.6m euro antitrust fine against this company for campaigning to discourage doctors and pharmacists from prescribing or substituting a generic version of its blood thinner Plavix. The Court rejected this company's appeal of a May 2013 decision by the French Competition Authority and fining it for abusing its dominance and using a 'strategy of denigration' against generic Plavix competitors in 2009 and 2010. [Listed under Information due to age of court finding]
Source: Law 360 (2014)

This company was fined 28m euros because two of its former employees were convicted of bribery by a German court in December 2013. The former employees had made illicit payments to a consultancy advising one of this company's clients between 2007 and 2010 to win new orders for the client. This led to Sanofi being unfairly given preference. [Listed under Information due to age of court finding]
Source: news article (2014)

This company is one of the pharmaceutical companies using free 'health camps' in India to test poor patients for diseases and then prescribe them drugs. In violation of the regulations of the Medical Council of India, the camps often do not have licensed doctors but use drug sales representatives to undertake health checks.
Source: British Medical Journal (2015)

Azmacort, Nasacort and Nasacort AQ are all steroid-based anti-inflammatory nasal sprays used to treat nasal congestion during the onset of a sinus infection, the common cold or hay fever. Their manufacturer, Aventis Pharmaceutical, which is a subsidiary of Sanofi-Aventis, agreed to $95.5 million in fines in 2009 after the company was found to have misreported the drugs' best prices, thereby avoiding paying millions of dollars in rebates to Medicaid between 1995 and 2000. [Listed under Information due to age of court finding]
Source: Drug Watch (2009)

In 2012, the US Department of Justice announced that this company agreed to pay US$109m to resolve allegations that they violated the False Claims Act by giving doctors free samples of knee injection product Hylagan to encourage them to buy and prescribe the treatment. The settlement also resolved allegations that the company submitted false sales reports for Hylagan that did not account for the free samples distributed contingent on purchases of the product. [Listed under Information due to age of court finding]
Source: First Word Pharma (2012)

Sanofi-Aventis has been investigated by USA's Food and Drug Administration for supplying the agency with fraudulent clinical trial data. Sanofi has run into legal trouble in the form of anti-trust lawsuits and investigations for its suppression of generic drugs and fiercely protecting its patents.
Source: Green America (2009)

This company is listed on the Federal Contractor Misconduct Database as having 8 instances of misconduct since 1995 amounting to US$290 million in penalties.
Source: Project on Government Oversight (POGO) (2014)

As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.
Source: We Mean Business (2021)

This company was named in Seramount's 100 Best Companies 2022 for being a mum-friendly employer. Listed companies provide inclusive benefits for families, including paid gender-neutral parental leave, phase-back programs, bereavement leave after miscarriage, reimbursement for fertility expenses, and increased mental health benefits for employees.
Source: Seramount (2022)

This company has a number of corporate responsibility claims and documents on its website.
Source: company website (2020)

This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)

This company received the seventh highest score in the Access to Medicine Index 2018, a ranking of the world's 20 largest pharmaceutical companies on their efforts to increase access to medicine in developing countries.
Source: Access to Medicine Index (2018)